Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium
Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients. The Canadian centers include Mount Sinai Hospital's Marvelle Koffler Breast Centre, the Princess Margaret Cancer Centre, Sunnybrook Odette Cancer Centre, and BC Cancer.
As part of the agreement, Epic will donate its No Cell Left Behind circulating tumor analysis platform to the clinical trial. The consortium will enroll about 1,000 patients over three years.